

- **Full Name:** Kyong Hwa Park, MD, PhD
  - **Current Position & Affiliation:** Professor, Oncology/Hematology, Department of internal medicine, College of medicine, Korea University
  - **Country:** Republic of Korea
- 

**• Educational Background:**

- 2002–2005 Ph. D., Graduate School, Korea University, College of Medicine, Seoul, Korea.
- 1999–2002: Master's Course. Graduate School of Korea University, Majored in Internal Medicine, Seoul, Korea.
- 1990–1998: MD, College of Medicine, Korea University, Seoul, Korea

**• Professional Experience:**

- 2016.2 – 2022.1: Chair, Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital
- 2014. 3- 2015. 2: Visiting scientist, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.
- 2013. 3– 2018. 2: Associate professor, Korea University
- 2009. 3– 2013. 2: Assistant professor, Korea University
- 2007. 9– 2009. 2: Full time lecturer, Oncology/Hematology, Korea University
- 2007. 6–2007. 8: Clinical Assistant Professor, Oncology/Hematology, Korea University Anam Hospital
- 2005. 6–2007. 6: Postdoctoral fellow, Tumor vaccine group in division of Oncology, department of medicine, University of Washington.
- 2004. 3–2005. 5: Clinical fellowship in Division of Oncology/Hematology, Internal Medicine, Korea University Hospital, Seoul, Korea.
- 1999. 3–2004. 2: Residency in Internal Medicine, Korea University Hospital, Seoul, Korea.
- 1998. 3–1999. 2: Rotating Internship, Korea University Hospital, Seoul, Korea.

**• Professional Organizations:**

- Member, Korean Society of Medical Oncology
- Board member, Korean Cancer Study Group
- Secretary General, Korean Cancer Association
- Member, American Association for Cancer Research
- Member, ASCO
- Member ESMO
- Member, SITC

**• Main Scientific Publications:**

1. JH Kang, HJ Lee, j Hong, YH Kim, Disis ML, Gim JA, Park KH. J Immunother Cancer . 2022 Sep;10(9):e004702. doi: 10.1136/jitc-2022-004702. Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+breast cancer murine model
2. Park KH, Choi JY, Lim AR, Kim JW, Choi YJ, S Lee, Kim YH, Sa K. J et al. Cancer Discov (2022) 12 (4): 938–948. Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program
3. Lim AR, Park KH at al. Support Care Cancer . 2022 Jun;30(6):5289-5297. Blood transfusion has an adverse impact on the prognosis of patients receiving chemotherapy for advanced colorectal cancer: experience from a single institution with a patient blood management program
4. Cecil DL, Park KH, Disis ML. J immunotherapy for Cancer. J Immunother Cancer 2021 Mar;9(3):e002355. Type I T-cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways
5. Kim JW, Lee S, Kim HS, Choi YJ, Yoo JH, Park KU, Park KH. Et al. Cytokine 142, June 21, 155487, Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)